These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38278450)

  • 1. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
    Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N
    Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
    Rugo HS; Loi S; Adams S; Schmid P; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Winer EP; Kockx MM; Peeters D; Chui SY; Lin JC; Nguyen-Duc A; Viale G; Molinero L; Emens LA
    J Natl Cancer Inst; 2021 Nov; 113(12):1733-1743. PubMed ID: 34097070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.
    Noske A; Wagner DC; Schwamborn K; Foersch S; Steiger K; Kiechle M; Oettler D; Karapetyan S; Hapfelmeier A; Roth W; Weichert W
    Breast; 2021 Dec; 60():238-244. PubMed ID: 34768219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey.
    Fusco N; Ivanova M; Frascarelli C; Criscitiello C; Cerbelli B; Pignataro MG; Pernazza A; Sajjadi E; Venetis K; Cursano G; Pagni F; Di Bella C; Accardo M; Amato M; Amico P; Bartoli C; Bogina G; Bortesi L; Boldorini R; Bruno S; Cabibi D; Caruana P; Dainese E; De Camilli E; Dell'Anna V; Duda L; Emmanuele C; Fanelli GN; Fernandes B; Ferrara G; Gnetti L; Gurrera A; Leone G; Lucci R; Mancini C; Marangi G; Mastropasqua MG; Nibid L; Orrù S; Pastena M; Peresi M; Perracchio L; Santoro A; Vezzosi V; Zambelli C; Zuccalà V; Rizzo A; Costarelli L; Pietribiasi F; Santinelli A; Scatena C; Curigliano G; Guerini-Rocco E; Martini M; Graziano P; Castellano I; d'Amati G
    Crit Rev Oncol Hematol; 2023 Oct; 190():104103. PubMed ID: 37595344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
    Pang JB; Castles B; Byrne DJ; Button P; Hendry S; Lakhani SR; Sivasubramaniam V; Cooper WA; Armes J; Millar EKA; Raymond W; Roberts-Thomson S; Kumar B; Burr M; Selinger C; Harvey K; Chan C; Beith J; Clouston D; O'Toole SA; Fox SB;
    Am J Surg Pathol; 2021 Aug; 45(8):1108-1117. PubMed ID: 34232604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens.
    Noske A; Steiger K; Ballke S; Kiechle M; Oettler D; Roth W; Weichert W
    J Clin Pathol; 2024 Mar; 77(4):239-245. PubMed ID: 36669878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
    Noske A; Ammann JU; Wagner DC; Denkert C; Lebeau A; Sinn P; Kreipe HH; Sommer U; Baretton G; Steiger K; Kiechle M; Hieke-Schulz S; Flores M; Roth W; Weichert W
    Histopathology; 2021 Mar; 78(4):567-577. PubMed ID: 32936950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays.
    Dabbagh TZ; Sughayer MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):462-466. PubMed ID: 33480602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.
    Naso JR; Wang G; Banyi N; Derakhshan F; Shokoohi A; Ho C; Zhou C; Ionescu DN
    Ann Diagn Pathol; 2021 Feb; 50():151590. PubMed ID: 33157383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
    Zajac M; Scott M; Ratcliffe M; Scorer P; Barker C; Al-Masri H; Rebelatto MC; Walker J
    Diagn Pathol; 2019 Sep; 14(1):99. PubMed ID: 31477145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.
    Paliogiannis P; Lobrano R; Bella MA; Fara A; Uras MG; Pinna MA; Tedde A; Madonia M; Zinellu A; Cossu A
    Ann Diagn Pathol; 2024 Apr; 69():152267. PubMed ID: 38266544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    Vainer G; Huang L; Emancipator K; Nuti S
    PLoS One; 2023; 18(6):e0285764. PubMed ID: 37267266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
    Sigurjonsdottir G; De Marchi T; Ehinger A; Hartman J; Bosch A; Staaf J; Killander F; Niméus E
    Breast Cancer Res; 2023 Oct; 25(1):123. PubMed ID: 37817263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
    Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
    Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
    Munari E; Rossi G; Zamboni G; Lunardi G; Marconi M; Sommaggio M; Netto GJ; Hoque MO; Brunelli M; Martignoni G; Haffner MC; Moretta F; Pegoraro MC; Cavazza A; Samogin G; Furlan V; Mariotti FR; Vacca P; Moretta L; Bogina G
    Am J Surg Pathol; 2018 Oct; 42(10):1384-1389. PubMed ID: 29901568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection.
    Munari E; Querzoli G; Brunelli M; Marconi M; Sommaggio M; Cocchi MA; Martignoni G; Netto GJ; Caliò A; Quatrini L; Mariotti FR; Luchini C; Girolami I; Eccher A; Segala D; Ciompi F; Zamboni G; Moretta L; Bogina G
    Front Immunol; 2022; 13():954910. PubMed ID: 35967344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.
    Yu SL; Hsiao YJ; Cooper WA; Choi YL; Avilés-Salas A; Chou TY; Coudry R; Raskin GA; Fox SB; Huang CC; Jeon YK; Ko YH; Ku WH; Kwon GY; Leslie C; Lin MC; Lou PJ; Scapulatempo-Neto C; Mendoza Ramírez S; Savelov N; Shim HS; Lara Torres CO; Cunha IW; Zavalishina L; Chen YM
    Pathology; 2023 Feb; 55(1):19-30. PubMed ID: 36319485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
    Huang X; Ding Q; Guo H; Gong Y; Zhao J; Zhao M; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
    Hum Pathol; 2021 Feb; 108():42-50. PubMed ID: 33221342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
    Eckstein M; Erben P; Kriegmair MC; Worst TS; Weiß CA; Wirtz RM; Wach S; Stoehr R; Sikic D; Geppert CI; Weyerer V; Bertz S; Breyer J; Otto W; Keck B; Burger M; Taubert H; Weichert W; Wullich B; Bolenz C; Hartmann A; Erlmeier F
    Eur J Cancer; 2019 Jan; 106():234-243. PubMed ID: 30528808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.